A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis

Primary Objective

To evaluate the effect of Saroglitazar Magnesium (2 mg and 4 mg) compared with Placebo on resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis at Week 76/EOT.

Study category: Digestive Health

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Scope

National

Locations

University of Colorado Hospital

Principal Investigator
Amanda Wieland,  MD

Amanda Wieland, MD

Study ID

Protocol Number: 21-3466

More information available at ClinicalTrials.gov: NCT05011305

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers